• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $OVID

    Ovid Therapeutics Inc.

    Subscribe to $OVID
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was incorporated in 2014 and is headquartered in New York, New York.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: ovidrx.com

    Peers

    $AQST

    Recent Analyst Ratings for Ovid Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    6/18/2024Outperform → Perform
    Oppenheimer
    4/30/2024$9.00Buy
    B. Riley Securities
    4/29/2024$9.00Buy
    H.C. Wainwright
    4/5/2024$8.00Outperform
    Wedbush
    12/21/2023$11.00Buy
    BTIG Research
    10/13/2023$8.00Outperform
    Oppenheimer
    8/25/2021$4.50 → $4.00Neutral
    Citigroup
    See more ratings